SUMMARY One hundred and forty six gastric ulcer patients were given open treatment using 1 g cimetidine daily to heal their ulcers. Of 130 who completed the acute treatment period of eight weeks, 112 (86%) had healed ulcers. Of these 112 patients with healed ulcers, 108 entered a one year double blind study to compare the effect of cimetidine maintenance therapy (400 mg at night) with placebo. Of the 84 patients available for assessment at the end of one year, 86% in the cimetidine treated group were in remission compared with 45% in the placebo treated group (X2=15-03; p<O.00l). There were simitar losses from non-compliance and drop out in both groups. The incidence of untoward effects and significant drug related laboratory abnormalities was low. The results indicate that cimetidine heals nearly 90% of acute gastric ulcers within eight weeks and that subsequent low dose maintenance treatment at night offers a considerable benefit over placebo therapy.
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Although the efficacy of cimetidine in the healing and prevention of recurrence of duodenal ulceration has been well documented,17 the evidence for similar efficacy in the treatment of gastric ulcer is less clear. There is now good evidence to suggest that gastric ulcers can be healed using cimetidine lg daily for four to eight weeks.810 The documentation covering maintenance treatment is rather sparse, however, and based on a variety of doses in relatively small patient populations. [11] [12] [13] [14] [15] In two studies cimetidine was compared with carbenoxolone and deglycerinised liquorice respectively.15 16 The results appear to show similar recurrence rates, but the studies were limited to six months only.
This multicentre study was designed to investigate in a one year double blind placebo controlled study the effect of prophylactic therapy with cimetidine on gastric ulcer recurrence.
Patients who had healed gastric ulcers after treatment for four to eight weeks treatment with cimetidine 1 g daily were included in the study. difference was already present at the beginning of the maintenance phase and not altered by subsequent drop outs (x2=9_16; p<0.05). Forty two patients in each treatment group completed the one year maintenance study or suffered an endoscopically proven relapse. Six (14%) of the cimetidine treated patients relapsed, 36 (86%) remained healed whereas with placebo treatment 23 (55%) relapsed and 19 (45%) patients remained healed, this difference being highly significant (X2= 15.03; p<0.001). No evidence of malignancy was shown in any of the ulcers that recurred during maintenance treatment.
Seven (24%) of 29 recurrences were asymptomatic, the proportion of asymptomatic recurrences being similar in both groups: two of six during cimetidine treatment and five of 23 during placebo treatment (Table 3) . The recurrence rate for gastric ulcers after healing is reported to be at least 60% without treatment.,
The need for effective drug prophylaxis, at least for selected patients, seems obvious. Only a few studies so far have dealt with maintenance treatment of gastric ulcer 11-14 reporting significantly fewer recurrences with cimetidine treatment than with placebo. This study strongly confirms these results. In this study, after randomisation to either cimetidine or placebo maintenance treatment, the distribution of ulcer localisation turned out to be unequal. Significantly fewer ulcers of the antrum were treated with cimetidine than with with placebo. The authors do not believe that this imbalance had a major influence on the final outcome of the study. It seems very unlikely that a small difference in the number of antral ulcers between the cimetidine and placebo treatment groups would have a noteworthy effect on relapse rates. This appears to be emphasised by the fact that no antral ulcers relapsed on cimetidine.
Twenty four per cent of the relapses in this trial were asymptomatic, about 80% occurring in the first six months. As this applies to both treatment groups, relapses on cimetidine do not appear to differ from those on placebo except that they occur significantly less frequently. It appears from this study that a significant improvement in remission' can be expected for maintenance treatment of healed gastric ulcers with cimetidine. As decisive prognostic factors for gastric ulcer patients are not known, it is still a matter of debate who should receive long term prophylactic treatment. We would suggest that those taking ulcerogenic drugs and those at major risk from ulcer complications would benefit most from long term maintenance therapy. 
